5-Amino-1MQ: Striking Mouse Data, Zero Human Trials
Every so often a compound arrives with a story so tidy that it sells itself. 5-Amino-1MQ has one of the tidiest in the current supplement market. It blocks a single enzyme, that enzyme is elevated in exactly the tissues that go wrong with age and excess weight, and blocking it in animals produces results that read like a wish list: fat loss without appetite suppression, more NAD+ inside the cell, old muscle that repairs itself again. The story is real in the sense that the studies exist and say roughly what people claim they say. What gets left out is the part that matters most, which is where those studies stop. This is an educational walk through the actual research on NNMT inhibition, what the mouse work found, why the compound is not the peptide it is often sold as, and what the empty top of the evidence ladder should mean to anyone reading about it. It is not medical advice and not a recommendation to obtain or use any compound.
An Enzyme That Gets Louder in the Wrong Places
Nicotinamide N-methyltransferase, shortened to NNMT, is not an exotic protein. It sits mostly in the liver, where it has a legitimate job, and it exists in every person reading this. What made it interesting to metabolic researchers was not its presence but its pattern. Fat tissue taken from obese subjects carries substantially more of the enzyme than fat tissue from lean subjects. Skeletal muscle in old animals carries more of it than muscle in young animals. Elevated levels also show up in a long list of tumor types, which is a separate research field with its own agenda. The pattern raised an obvious question. Is the enzyme rising because the tissue is in trouble, or is the tissue in trouble partly because the enzyme is rising? Correlation alone cannot answer that. The way you answer it is by removing the enzyme and watching what happens, which is what a small group of labs set out to do starting in the mid-2010s.
The Enzyme Climbs in Exactly the Tissues You Would Not Want It To
NNMT is present in everyone, mostly in the liver, and it does necessary work. The pattern that drew researchers to it is where the levels rise. Fat tissue in obesity carries far more of it than lean fat tissue, and aging skeletal muscle carries far more than young muscle. Bars index each comparison against its own baseline at 100. These are directional figures drawn from the published comparisons, not a single measured dataset.
The Methyl Group That Goes Missing
The mechanism is easier to follow than the name suggests. NNMT takes nicotinamide, a form of vitamin B3 that your cells recycle back into NAD+, and sticks a methyl group on it. That produces a compound called 1-methylnicotinamide, which is largely a dead end. The nicotinamide that gets methylated is nicotinamide that never makes it back into the NAD+ pool. The methyl group itself comes from S-adenosylmethionine, the cell's main methyl donor, which is also the currency used for the methylation reactions that regulate gene expression. So an overactive enzyme drains two things at once. It taps the raw material for NAD+ regeneration and it burns through the methyl supply that other processes depend on. In cultured fat cells, blocking the enzyme moved all of these in the expected direction. The dead-end waste product fell sharply, NAD+ rose, the methyl donor pool rose, and the cells built noticeably less new fat. That is a clean result, and clean results in a dish are also the least reliable predictor of anything in a body.
What Shifts Inside a Fat Cell When the Enzyme Is Blocked
In cultured fat cells, blocking NNMT produced a consistent set of moves. The methylated waste product dropped, the NAD+ pool rose, the methyl donor pool rose with it, and the cell built less new fat. That combination is the whole reason anyone cared about this enzyme. Bars show the approximate direction and scale of change reported in cell work, which is the cleanest and least translatable layer of this evidence.
Eleven Days in Obese Mice
The animal work is what people are actually referring to when they cite the research. Neelakantan and colleagues published a series of small-molecule NNMT inhibitors built on a methylquinolinium scaffold, which is the chemical family 5-Amino-1MQ belongs to. Mice were made obese on a high-fat diet, then given a potent inhibitor by injection at twenty milligrams per kilogram, three times daily, for roughly eleven days. Over that window the treated animals lost around seven percent of their body weight and close to a third of their white fat mass, while controls on the same diet kept gaining. Fat cells shrank, plasma cholesterol dropped, and the reported food intake did not differ between the groups. That last detail is what everyone latched onto, because a fat-loss effect that does not run through appetite is a genuinely different mechanism from every drug currently dominating the category. Later work extended the picture, reporting dose-dependent limits on fat gain along with better oral glucose tolerance, improved insulin sensitivity, lower liver triglycerides, and less fatty change in the liver.
Eleven Days in Diet-Induced Obese Mice
The result that built the reputation came from obese mice given a potent NNMT inhibitor by injection three times a day for about eleven days. Control animals kept gaining on the same high-fat diet. Treated animals lost roughly seven percent of body weight and close to a third of their fat mass, and the reported food intake did not differ between groups. Lines trace change from baseline over the treatment window.
- Control body weight
- Treated body weight
- Treated fat mass
The Muscle Finding Is the More Interesting One
The fat result gets the headlines and the muscle result deserves them more. A different arm of this work asked what NNMT inhibition does in aged animals rather than obese ones. Old muscle heals badly, and a large part of why is that satellite cells, the resident stem cells that repair damaged fibers, drift into senescence and stop dividing. Aged muscle also carries elevated NNMT, which links back to a depleted local NAD+ environment and to sirtuin signaling that depends on it. When researchers gave old mice an NNMT inhibitor, those dormant stem cells started proliferating and fusing into fibers again. The repaired fibers came back with close to double the cross-sectional area of untreated controls, and peak torque in the treated leg muscle rose by roughly seventy percent. Read that as a mechanistic proof of concept rather than a preview of your own results. It is a strong signal that the enzyme is doing something causal in aged tissue, and it is still an experiment in mice with an injected research compound.
The Aged Muscle Result Nobody Talks About
A separate line of work gave the inhibitor to old mice and looked at muscle rather than fat. Dormant muscle stem cells started dividing again, the repaired fibers came back thicker, and the treated leg produced substantially more force than the untreated one. Control values are indexed to 100 so the comparison is readable. This is a rodent aging model, which is a long way from a person in their fifties.
- Untreated aged mice
- Aged mice on the inhibitor
It Is Not a Peptide, Whatever the Store Says
5-Amino-1MQ is sold on peptide sites, listed in peptide catalogues, and discussed on peptide forums, and it is not a peptide. A peptide is a chain of amino acids. This is a small synthetic molecule, a quinolinium ring carrying a permanent positive charge, closer in character to a conventional drug candidate than to anything in the BPC-157 or CJC-1295 category. The distinction is not pedantry. It changes how the compound is absorbed, how it distributes, how it clears, and which organ carries the load of processing it. It also explains why this one shows up in capsules rather than vials, since a small molecule can survive a trip through the digestive tract in a way most peptides cannot. Anyone reasoning about safety by analogy to peptides they have taken before is reasoning from the wrong reference class. The relevant comparison is a small-molecule enzyme inhibitor that has never completed a formal toxicology program in humans.
The Distance Between That Mouse and You
Take the headline dosing and follow it forward. Twenty milligrams per kilogram, three times a day, delivered by subcutaneous injection in a mouse. Mice run their metabolism far faster than we do, so you cannot multiply by body weight and call it a human dose, and the standard scaling adjustments cut the figure substantially. Even after that correction, the daily amount implied by the animal protocol sits well above the fifty to one hundred fifty milligram oral capsules being sold, and the route is different, and the dosing frequency is different. Nobody has published the pharmacokinetics that would connect the two. How much of an oral dose reaches circulation, what happens to it in the liver, how long it stays, how much of it actually reaches fat tissue or muscle: those numbers do not exist in the public literature for this compound in humans. What is being sold is not a scaled-down version of the studied protocol. It is a different compound presentation at a different dose by a different route, marketed on results from the original.
Zero Human Trials, and a Full Shelf of Capsules
This is the part that ought to be printed at the top of every page selling it. As of this writing there are no published human clinical trials of 5-Amino-1MQ. Not a phase 3, not a phase 2, not a phase 1 safety study. There is no established human dose, no documented side-effect profile, no drug interaction data, and no information about what sustained inhibition of a liver enzyme does in a person over months. It has not been approved by the FDA for anything and is sold as a research chemical, which is a regulatory category rather than a quality claim. That status also means nothing verifies what is in the capsule. Independent testing across the grey research-chemical market has repeatedly found products that are underdosed, mislabeled, or contaminated, and a compound with no legitimate supply chain has no reason to be an exception. The safety silence is worth sitting with. An absence of reported harm in a compound nobody has formally studied in humans is not evidence of safety. It is an absence of data.
How Deep the Evidence Actually Runs
Every compound sits somewhere on a ladder that runs from a dish of cells up to a large controlled trial in people. This one has real work on the bottom rungs and nothing at all on the top. There are no published human trials of 5-Amino-1MQ, which means no dosing data, no safety record, and no efficacy figure in a human being. Bars are a qualitative read of how much published work exists at each stage.
What Would Actually Settle This
The questions here are answerable, which is what makes the situation frustrating rather than mysterious. A phase 1 study would establish what an oral dose does in the bloodstream and what the body tolerates. A trial with body-composition endpoints would show whether the fat effect survives translation, and whether the striking part of the mouse data, losing fat without eating less, holds in a species that did not evolve on a rodent metabolic clock. There are also real questions to close on the other side of the ledger. NNMT does useful work in the liver, and the long-term consequences of dialing down a methylation pathway are not obvious. The enzyme's involvement in tumor biology cuts in a complicated direction and deserves its own careful answer rather than a reassuring paragraph. Pharmaceutical programs targeting NNMT do exist and are advancing, which is the appropriate way to find all of this out. The information will eventually be available. It is not available now.
How to Read a Compound at This Stage
The useful takeaway is not about this molecule specifically. It is about how to place any compound that arrives with an impressive mechanism and a thin clinical record. Ask which species the result came from. Ask what dose and what route. Ask whether the marketed product resembles the studied protocol in any meaningful way. Ask what the compound would need to demonstrate to move up a rung, and whether anyone is running that study. Applied here, the answers are consistent: the biology is legitimate and genuinely interesting, the animal work is real, and the gap between that work and a capsule on a website is enormous and mostly unmeasured. Being early on something is only an advantage if the thing turns out to work and turns out to be safe, and both of those are currently unknown rather than promising. If any of this is relevant to your situation, the conversation belongs with a licensed clinician who can look at your labs and your history. Everything above is educational background for that conversation and not a substitute for it.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Does Telomere Length Determine Lifespan? Short Telomeres Track With Earlier Death. The Genetics Say Longer Ones Raise Cancer Risk.
Does telomere length determine lifespan? Short telomeres track with earlier death, yet genetic studies show longer ones raise the risk of several cancers.
Low-Dose Aspirin Added 8 Percent to Male Mouse Lifespan. In 19,114 Healthy Older Adults, It Added No Healthy Years and Deaths Ran Higher.
Does low-dose aspirin help longevity? It extended male mouse lifespan 8%, but the ASPREE trial in 19,114 healthy older adults found no gain and more bleeding.
Is NAD+ a Peptide? No. It Is a Coenzyme Built From Two Nucleotides, and the Peptide Label Comes From the Clinic, Not the Chemistry
Is NAD+ a peptide? No. NAD+ is a coenzyme built from two nucleotides. What NAD+ is used for, what IV NAD+ studies found, and how it differs from SS-31.